Literature DB >> 35001353

Paeonol Ameliorates Cuprizone-Induced Hippocampal Demyelination and Cognitive Deficits through Inhibition of Oxidative and Inflammatory Events.

Soosan Pourmohammadi1, Mehrdad Roghani2, Zahra Kiasalari3, Mohsen Khalili3.   

Abstract

Multiple sclerosis (MS) is a chronic and inflammatory disorder of the central nervous system with autoimmune nature that is typified by varying degrees of demyelination and axonal damage. Paeonol is an active ingredient in some medicinal plants with anti-inflammatory and neuroprotective property. This study was conducted to reveal whether paeonol can alleviate hippocampal demyelination and cognitive deficits in cuprizone-induced murine model of demyelination as a model of MS. C57BL/6 mice received oral cuprizone (400 mg/kg) for 6 weeks, and paeonol was administered p.o. at two doses of 25 or 100 mg/kg, starting from the second week post-cuprizone for 5 weeks. After assessment of learning and memory in different tasks, oxidative stress and inflammation were evaluated besides immunohistochemical assessment of hippocampal myelin basic protein (MBP). Paeonol (100 mg/kg) properly ameliorated cognitive deficits in Y maze, novel object discrimination (NOD) test, and Barnes maze with no significant improvement of performance in passive avoidance task. In addition, paeonol treatment at the higher dose was also associated with partial restoration of hippocampal level of oxidative stress and inflammatory markers including MDA, ROS, GSH, SOD, catalase, NF-kB, and TNF. Besides, paeonol improved MMP as an index of mitochondrial integrity and health and reduced MPO as a factor of neutrophil infiltration. Furthermore, paeonol treatment prevented hippocampal MBP immunoreactivity, indicating its prevention of demyelination. In conclusion, the current study showed the preventive effect of paeonol against cuprizone-induced demyelination and cognitive deficits through reversing most oxidative stress- and inflammation-related parameters in addition to its improvement of mitochondrial health.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cognition; Cuprizone; Demyelination; Multiple sclerosis; Paeonol

Mesh:

Substances:

Year:  2022        PMID: 35001353     DOI: 10.1007/s12031-021-01951-2

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  43 in total

1.  Toxicity of cuprizone a Cu(2+) chelating agent on isolated mouse brain mitochondria: a justification for demyelination and subsequent behavioral dysfunction.

Authors:  Mehrdad Faizi; Ahmad Salimi; Enayatolla Seydi; Parvaneh Naserzadeh; Mehdi Kouhnavard; Atena Rahimi; Jalal Pourahmad
Journal:  Toxicol Mech Methods       Date:  2016-04-18       Impact factor: 2.987

2.  Soy isoflavone attenuates brain mitochondrial oxidative stress induced by β-amyloid peptides 1-42 injection in lateral cerebral ventricle.

Authors:  Juan Ding; Huan-Ling Yu; Wei-Wei Ma; Yuan-di Xi; Xia Zhao; Lin-Hong Yuan; Jin-Fang Feng; Rong Xiao
Journal:  J Neurosci Res       Date:  2012-12-13       Impact factor: 4.164

3.  Resveratrol Promotes Remyelination in Cuprizone Model of Multiple Sclerosis: Biochemical and Histological Study.

Authors:  Heba R Ghaiad; Mohammed M Nooh; Maha M El-Sawalhi; Amira A Shaheen
Journal:  Mol Neurobiol       Date:  2016-04-11       Impact factor: 5.590

Review 4.  Remyelination in experimental models of toxin-induced demyelination.

Authors:  W F Blakemore; R J M Franklin
Journal:  Curr Top Microbiol Immunol       Date:  2008       Impact factor: 4.291

5.  Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis.

Authors:  Massimiliano Calabrese; Federica Agosta; Francesca Rinaldi; Irene Mattisi; Paola Grossi; Alice Favaretto; Matteo Atzori; Valentina Bernardi; Luigi Barachino; Luciano Rinaldi; Paola Perini; Paolo Gallo; Massimo Filippi
Journal:  Arch Neurol       Date:  2009-09

6.  Increasing incidence of multiple sclerosis among women in Buenos Aires: a 22 year health maintenance organization based study.

Authors:  E Cristiano; L Patrucco; J Miguez; D Giunta; J Peroni; J I Rojas
Journal:  Neurol Sci       Date:  2016-06-23       Impact factor: 3.307

7.  Neuroprotective Effects of Melatonin during Demyelination and Remyelination Stages in a Mouse Model of Multiple Sclerosis.

Authors:  Hanin Abdulbaset Abo Taleb; Badrah Saeed Alghamdi
Journal:  J Mol Neurosci       Date:  2019-11-11       Impact factor: 3.444

8.  Neuroprotective Effects of Telmisartan and Nifedipine Against Cuprizone-Induced Demyelination and Behavioral Dysfunction in Mice: Roles of NF-κB and Nrf2.

Authors:  Amira E Abd El Aziz; Rabab Hamed Sayed; Nada A Sallam; Nesrine S El Sayed
Journal:  Inflammation       Date:  2021-03-11       Impact factor: 4.092

9.  Transplanted miR-219-overexpressing oligodendrocyte precursor cells promoted remyelination and improved functional recovery in a chronic demyelinated model.

Authors:  Hong-Bin Fan; Li-Xia Chen; Xue-Bin Qu; Chuan-Lu Ren; Xiu-Xiang Wu; Fu-Xing Dong; Bao-Le Zhang; Dian-Shuai Gao; Rui-Qin Yao
Journal:  Sci Rep       Date:  2017-02-01       Impact factor: 4.379

10.  MsrA Suppresses Inflammatory Activation of Microglia and Oxidative Stress to Prevent Demyelination via Inhibition of the NOX2-MAPKs/NF-κB Signaling Pathway.

Authors:  Hua Fan; Damiao Li; Xinlei Guan; Yanhui Yang; Junqiang Yan; Jian Shi; Ranran Ma; Qing Shu
Journal:  Drug Des Devel Ther       Date:  2020-04-05       Impact factor: 4.162

View more
  2 in total

1.  Multi-elements characteristic and potential risk of heavy metals in MOUTAN CORTEX from Anhui Province, China.

Authors:  X Xue; G Liu; Q Tang; H Shi; D Wu; C Jin; H Zhao; Y Wei; Y Zhang
Journal:  Int J Environ Sci Technol (Tehran)       Date:  2022-08-06       Impact factor: 3.519

Review 2.  Potential Utility of Natural Products against Oxidative Stress in Animal Models of Multiple Sclerosis.

Authors:  Zheng Zha; Sisi Liu; Yijiang Liu; Chen Li; Lei Wang
Journal:  Antioxidants (Basel)       Date:  2022-07-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.